Share This Post

Business Wire

Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm

FRIENDSWOOD, Texas–(BUSINESS WIRE)—- $CSTL #DecisionDxMelanoma–Castle announced the publication of a study validating performance of the i31-SLNB algorithm to determine sentinel lymph node biopsy positivity risk.

Share This Post